Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 ...
The math behind sheltering VO in a Roth IRA reveals a layered advantage most investors never think to calculate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results